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Obesity is one of the major challenges to human health worldwide; however, there are currently no eﬀective pharmacological
interventions for obesity. Recent studies have improved our understanding of energy homeostasis by identifying sophisticated
neurohumoral networks which convey signals between the brain and gut in order to control food intake. The hypothalamus is a
key region which possesses reciprocal connections between the higher cortical centres such as reward-related limbic pathways, and
the brainstem. Furthermore, the hypothalamus integrates a number of peripheral signals which modulate food intake and energy
expenditure. Gut hormones, such as peptide YY, pancreatic polypeptide, glucagon-like peptide-1, oxyntomodulin, and ghrelin, are
modulated by acute food ingestion. In contrast, adiposity signals such as leptin and insulin are implicated in both short- and long-
term energy homeostasis. In this paper, we focus on the role of gut hormones and their related neuronal networks (the gut-brain
axis) in appetite control, and their potentials as novel therapies for obesity.
1. Introduction
Despite recent progress in our understanding of the phys-
iological mechanisms regulating body weight and energy
expenditure, obesity remains a major worldwide health
crisis with an array of vascular, metabolic, and psychosocial
consequences [1, 2]. Overweight or obese individuals (body
mass index 25–30) have an increased risk of developing
diabetes, coronary heart disease, and hypertension [2, 3].
Adults with a body mass index of 40 or higher have been
associated with a high risk of developing diabetes, hyperten-
sion, dyslipidaemia, asthma, arthritis, and poor health status,
when compared with normal weight individuals [4].
Body weight is tightly regulated by complex homeostatic
mechanisms. Obesity is a state in which energy intake
chronically exceeds energy expenditure. Even a subtle mis-
match (less than 0.5%) in caloric intake over expenditure is
suﬃcient to cause weight gain [5]. The rising prevalence of
obesity is likely to result from contemporary environmental
and lifestyle factors such as increased access to palatable
foods and reduced requirements for physical exercise, when
compared with ancient hunter-gatherer lifestyles charac-
terised by unpredictable periods of feast and famine.
In addition to local paracrine actions and peripheral
endocrine eﬀects mediated through the bloodstream, gut
hormones play a pivotal role relaying information on nutri-
tional status to important appetite controlling centres within
the central nervous system (CNS), such as the hypothalamus
and the brainstem.
In this article, we will summarise our current under-
standing of the physiological interactions between the gut
and brain, termed the “gut-brain axis,” focussing particularly
on the interactions of gut hormones with the CNS and vagus
nerve [6]. We will not discuss signal transduction pathways,
enteric nervous systems related to controlling food intake,
or neural signalling pathways in organs associated with the
gastrointestinal tract such as liver or pancreas.
2. Gut Hormones
2.1. Pancreatic Polypeptide-Fold Peptides. The PP-fold family
comprises neuropeptide Y (NPY), peptide YY (PYY), and
pancreatic polypeptide (PP). They are composed of a chain
of 36 amino acids residue and share amino acid homology,
amidated C-terminal ends. The tertiary structure PP-fold is
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U shaped with an extended polyproline helix and an α helix
connected by a β turn [7]. In addition, a hairpin-like PP-fold
motif is vital for receptor binding. PYY and PP are secreted
from gastrointestinal tract, whereas NPY is predominantly,
widely distributed in CNS [8]. This family acts via G protein-
coupled receptors; Y1, Y2, Y4, Y5, and Y6 [9].The Y3 receptor
has not yet been cloned, and the Y5 receptor has been found
as a nonfunctional truncated form.
2.2. Peptide Tyrosine Tyrosine (PYY). PYY is an appetite sup-
pressing hormone, which was isolated originally from
porcine upper small intestine [8]. Its name is derived from
its characteristic tyrosine (Y) residues at both the C and N
terminals. PYY is released from the L cells of the distal gut in
response to ingested nutrients with two other gut hormones,
GLP-1 and OXM. PYY immunoreactivity is highest in the
rectum, and decreases proximally to low levels in the duo-
denum and jejunum. PYY immunoreactivity is also found in
the CNS regions such as the hypothalamus, medulla, pons,
and spinal cord [10]. Two endogenous circulating forms,
PYY1–36 and PYY3–36, are synthesized within the gut. PYY1–36
is the biologically active major circulating form, which is
produced by cleavage of the N-terminal tyrosine-proline
residues from PYY1–36 by the enzyme dipeptidyl-peptidase
IV (DPP-IV) [11]. PYY1–36 has aﬃnity to all Y receptors,
while PYY3–36 acts mainly via the high-aﬃnity hypothalamic
Y2 receptor.
The PYY secretion pattern suggests a role in satiety.
Circulating PYY concentrations are low in fasted state and
increase rapidly following a meal with a peak at 1-2 hours
and remain elevated for several hours [12]. PYY release is
increased in proportion to calorie intake [12]. PYY may
have a role in the pathogenesis of a number of anorectic
conditions such as inflammatory bowel disease, steatorrhea,
tropical sprue, and cardiac cachexia, since plasma PYY
levels are elevated in patients with these conditions [13–
15]. Peripheral PYY3–36 administration shows a reduction
in food intake and body weight gain in rats [16]. In both
lean and obese human subjects, intravenous administration
of PYY3–36 reduces appetite and food intake [16, 17] with
observed plasma PYY3–36 levels similar to the physiological
levels after a meal; this data suggests that the physiological
eﬀect of PYY is to suppress food intake. Of note, no nausea
was reported in subjects following PYY3–36 administration.
This suggests that, unlike leptin, the sensitivity of subjects to
PYY is preserved in obese subjects. Some investigators failed
to show an anorectic eﬀect of PYY, possibly due to inadequate
acclimatization of control and treated animals [18].
The “ileal brake” is the negative feedback mechanism
in which the presence of nutrients into the colon inhibits
motility and transit of further nutrients within the upper
gastrointestinal tract [19]. Fat is known to be themost potent
trigger of the ileal brake. GLP-1 and PYY may contribute to
this phenomenon [20].
PYY has been reported to regulate energy expenditure,
delay gastric emptying, reduce acid secretion, and inhibit
gallbladder contraction and pancreatic exocrine secretions
[21, 22]. Circulating PYY levels are low in obese subjects
[17, 23], and they are higher in patients with anorexia
nervosa when compared with control subjects [24]. Studies
of circulating levels of PYY in obese and lean people have
yielded inconsistent results [25, 26]; however, a blunted
postprandial rise in PYY in obese subjects suggests a possible
association with impaired postprandial satiety during obesity
[21].
PYY3–36 exerts anorectic eﬀects via a direct action in
the hypothalamic arcuate nucleus (ARC). Peripheral admin-
istration of PYY3–36 increases c-fos expression (a marker
of neuronal activation) in the ARC and direct injection of
PYY3–36 into the ARC inhibits food intake. This eﬀect is likely
to be mediated through the Y2 receptor since the anorectic
eﬀect of peripheral PYY3–36 administration is blocked in
Y2 receptor-null mice, and intraarcuate injection of a Y2
receptor selective agonist also supresses food intake [16].
Although conflicting results have been reported [27], the
vagal-brainstem may also signal the actions of PYY on
food intake. Two independent laboratories have observed
that vagotomy abolishes anorexia c-fos activation following
peripheral PYY3–36 administration [28, 29].
In contrast to the anorectic eﬀects observed by peripheral
and intraarcuate PYY3–36 administration, direct administra-
tion of PYY3–36 into the third ventricle of the brain [30] or
paraventricular nucleus (PVN) [31] increases in food intake.
This paradoxical action may be explained by considering
that such eﬀects might be endogenously mediated by the
orexigenic CNS-distributed peptide, NPY, through an action
on Y1 receptor and Y5 receptors [32]. PYY may also act in
the brain areas other than the hypothalamus and brainstem.
In a clinical study using functional MRI by Batterham et
al. [33], PYY3–36 infusion modulated neural activity within
corticolimbic and higher cortical brain regions.
Exogenous PYY3–36 NH2 and exendin-4, a GLP-1 receptor
agonist, have synergistic eﬀects to suppress food intake in
mice [34]. Furthermore a recent study utilizing functional
MRI by De Silva et al. [35] showed that coadministration of
PYY3–36 and GLP-17–36 amide to fasted human subjects results
in similar reductions in subsequent energy intake and brain
activity, as observed physiologically following feeding.
Neuropeptide Y2 receptors have cardiovascular eﬀects in
addition to their metabolic eﬀects. Y2 agonism is implicated
in the pathogenesis of hypertension in hypertensive rats [36].
Nordheim and Hofbauer [37] reported that Y2 receptor
stimulation by PYY3–36 demonstrated cardiovascular eﬀects
of endogenous NPY in rats on diﬀerent dietary regimens.
In food-restricted rats, PYY3–36 increased mean arterial
pressure and heart rate, whereas PYY3–36 did not influence
mean arterial pressure and heart rate in high-fat diet rats.
However, human studies thus far have not demonstrated any
hypertensive changes as a result of PYY administration.
2.3. Pancreatic Polypeptide (PP). PP is secreted from PP cells
in the pancreatic islets of Langerhans in response to a meal.
Anorectic eﬀects of PP are thought to be mediated by directly
through the Y4 receptor in the brainstem and hypothalamus.
In addition, it may act also via the vagus nerve, as the
anorectic eﬀects of PP are abolished by vagotomy in rodents
[38]. PP has a high aﬃnity for the Y4 receptor, of which
expression is found in the area postrema (AP), nucleus
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of the tractus solitarius (NTS), dorsal motor nucleus of
vagus (DVN), ARC, and PVN [39]. An autoradiography
study also identified saturable PP binding sites at the
interpeduncular nucleus, AP, NTS, and DVN [40]. Like PYY,
paradoxical eﬀects on food intake are observed following
PP injection, depending on its route of administration. In
contrast to the anorectic eﬀects observed with peripheral
PP administration, central PP administration stimulates
food intake [41]. Although the exact mechanism of this
phenomenon is unclear, these diﬀerential eﬀects may be
mediated by activation of distinct populations of receptors.
PP also has other physiological eﬀects, such as delaying
gastric emptying, attenuating pancreatic exocrine secretion,
and inhibiting gallbladder contraction [42].
Plasma PP levels show diurnal variations: lowest levels are
observed in the early morning and highest in the evening.
The release of postprandial PP is biphasic. Circulating PP
concentrations increase after a meal in proportion to the
caloric intake, and increased levels remain for up to 6
hours postprandially [43]. Circulating PP levels seem to be
inversely proportional to adiposity; higher levels are reported
in subjects with anorexia nervosa [44]. Some, but not all
[45, 46], studies have demonstrated significant reductions
in circulating levels of PP in obese subjects [47, 48].
Furthermore, obese patients with Prader-Willi syndrome
(PWS) have been reported to have reduced PP release both
basally and postprandially [49].
In mice, acute and chronic peripheral PP administration
results in reduced food intake. In leptin-deficient ob/ob mice,
repeated intraperitoneal PP injection decreases body weight
gain and improves insulin resistance and hyperlipidaemia
[38]. Furthermore, transgenic mice overexpressing PP have
reduced food intake when compared with wild-type con-
trols [50]. In normal-weight human subjects, intravenous
infusion of PP achieved three times higher circulating PP
concentrations when compared with postprandial levels in
the same subjects after a buﬀet lunch (which reduced food
intake by 25% over 24 hours) [51]. Furthermore, twice-daily
infusion of PP in volunteers with PWS resulted in a 12%
reduction in food intake [52]. Agonists to the Y4 receptor
designed tomimic the actions of PP have been developed and
are under further investigation as potential novel therapies
for obesity.
2.4. Proglucagon-Derived Peptides. The proglucagon gene is
expressed in the pancreas, in the L-cells of the small intestine
and in the NTS of the brainstem [53, 54]. GLP-1, GLP-
2, OXM, and glucagon are proglucagon-derived peptides.
Glucagon is themain product in the pancreas, whereas OXM,
GLP-1, and GLP-2 are the major products in the brain and
intestine [55].
2.4.1. Glucagon-Like Peptide-1 (GLP-1). GLP-1 is cosecreted
with PYY from the L cells in the intestine in response to
nutrient ingestion. GLP-1 has two biologically active forms,
GLP-17–37 and GLP-17–36 amide. The latter truncated form
is the major circulating form in humans, although both
active isoforms of GLP-1 have equivalent potency [56].
In addition, GLP-17–36 amide is distributed within the CNS.
Immunoreactive neurons for GLP-17–36 amide are located
in the PVN, DMN, NTS, dorsal vagal complex (DVC),
pituitary, and thalamus [57]. GLP-1 receptor mRNA is
distributed throughout the rostrocaudal hypothalamus, with
dense accumulation in the ARC, PVN, and supraoptic nuclei
[58]. While peripheral administration of GLP-1 in rats leads
to increased c-fos expression in the ARC [28], intracere-
broventricular (ICV) administration results in increased c-
fos expression in the PVN, NTS, and AP [59]. Ascending
NTS-PVN projections contain GLP-1 [60] are implicated in
controlling food intake. In the CNS, leptin receptor (Ob-Rb)
was expressed in GLP-1-containing neurons in the NTS in
animals and leptin activated GLP-1 containing neurons in
the NTS [61]. Signals arising from the hepatoportal GLP-
1R promote glucose clearance, which are independent of
changes in insulin secretion [62, 63].
GLP-1 exerts its eﬀect by activation of the GLP-1R
to stimulate adenylyl cyclase activity and thereby cAMP
production [64]. GLP-1R is widely distributed particularly
in the brain, gastrointestinal tract, and pancreas [64, 65].
In the brain, binding sites for GLP-1Rs have been found in
the hypothalamus, striatum, brainstem, substantia nigra, and
subventricular zone among other structures [64, 66]. GLP-
1Rs are present on both glia and neuronal cell types [66].
In addition, GLP-1Rs are expressed in the nodose ganglion
[67]. Furthermore bilateral subdiaphragmatic total truncal
vagotomy or brainstem-hypothalamic pathway transetioning
abolishes the suppressing actions of GLP-1 on food intake
[28]; this suggests that the vagus contributes to the actions of
GLP-1 on food intake.
Circulating GLP-1 levels rise postprandially and fall in
the fasted state. Recent evidence also suggests that GLP-
1 levels rise in anticipation of a meal [68]. GLP-1 not
only reduces food intake, but also suppresses glucagon
secretion and delays gastric emptying [69]. Intravenous
administration of GLP-1 is associated with a dose-dependent
reduction of food intake in both normal weight and obese
subjects [70], although obese subjects may be less responsive
[64].
GLP-1 possesses a potent incretin eﬀect in addition to its
anorectic action; it stimulates insulin secretion in a glucose-
dependent manner following ingestion of carbohydrate.
However, its use as obesity treatment was limited for many
years by its short plasma half-life of 1-2 minutes [71], which
is partly attributed to enzymatic degradation by DPP-IV and
renal clearance that rapidly inactivate and remove GLP-1
from plasma circulation [72, 73]. Continuous subcutaneous
infusion of GLP-1 to patients with type 2 diabetes for 6 weeks
reduces appetite, and body weight, and improves glycaemic
control [74]. However, DPP-IV-resistant analogues of GLP-
1 have been developed. Exendin-4 (exenatide), a naturally
occurring peptide originally isolated from the saliva of the
Gila monster lizard, is a DPP-IV-resistant GLP-1R agonist
[75]. Exenatide improves glycaemic control and decreases
body weight in patients with type 2 diabetes. [76]. GLP-1
possesses trophic eﬀects on pancreatic beta cells in animal
models [77]. GLP-1 and exendin-4 have been recently shown
to promote cellular growth and reduce apoptosis in nervous
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tissues [78], but trophic eﬀects on pancreatic beta cells have
not been demonstrated clinically in human subjects. GLP-
1 agonists are, therefore, a good example of how research
in this area has been translated into clinical practice. A
three-year duration of treatment with exenatide has been
reported to improve beta cell function; however, when
adjusting for weight loss associated with exenatide therapy,
this eﬀect remains speculative [79]. DPP-IV inhibitors, such
as sitagliptin and vildagliptin, which are licensed for the
treatment of type 2 diabetes, do not result in decrease in body
weight. This may be explained by considering that DPPIV
is also involved in the modification of other gut hormones
such as PYY, and cytokines which may have opposite eﬀects
to GLP-1 [80].
GLP-1-based therapies are promising novel treatments
for type 2 diabetes, however, long-term outcome data
are not yet available. The reported side eﬀects of GLP-1
agonists are nausea and vomiting. Animal safety studies with
liraglutide have identified C-cell carcinoma of the thyroid.
Acute pancreatitis has been reported in humans treated with
liraglutide or exenatide [81]. Further outcome data will,
therefore, be important in confirming the long-term safety
of GLP-1-based therapies.
2.4.2. Oxyntomodulin (OXM). OXM is a 37-amino acid
peptide originally isolated from porcine jejunoileal cells and
is found to show glucagon-like activity in the liver [82].
OXM is another product of the proglucagon gene and is
cosecreted with GLP-1 and PYY by the L-cells of the distal
gastrointestinal tract, in response to ingested food and in
proportion to caloric intake [83]. OXM has anorectic eﬀects
and shows incretin activity with a much lower potency when
compared with GLP-1 [84]. OXM also inhibits gastric acid
secretion and delays in gastric emptying [85].
Administration of OXM is associated with decreased
food intake and increases energy expenditure in both rodents
and humans [86–88]. The anorectic eﬀect of OXM is blocked
by the GLP-1R antagonist, exendin9–39 [89], and is not
observed in GLP-1R null mice [90]; this suggests that the
anorectic eﬀects of OXM may be mediated by the GLP-1R.
However, OXM has relatively low in vitro aﬃnity for the
GLP-1R which is 50 folds lower than the aﬃnity of GLP-
1 for GLP1R, despite the anorectic potency of OXM being
comparable to the potency of GLP-1 [91]. Several actions
of OXM seem independent of the GLP-1R [87, 92, 93];
the cardiovascular eﬀects of OXM are preserved in GLP-
1R knockout mice [92]. These data suggest that a further
receptor through which OXM mediates its anorectic eﬀect
has yet to be identified. Furthermore, direct administration
of the GLP-1R antagonist, exendin9–39, to the ARC fails to
inhibit the anorectic eﬀects of OXM but inhibits that of
GLP-1 [87]. Like GLP-1, OXM is inactivated by DPP-IV.
OXM analogues resistant to DPP-IV degradation are being
developed as potential obesity treatments [94].
2.4.3. Glucagon. The role of glucagon in glucose homeostasis
is well established; glucagon is produced by alpha cells of
the pancreatic islets and increases glucose concentration
in response to hypoglycaemia. Glucagon enhances the
body’s physiological response to stress, by increasing energy
expenditure [95, 96]. However, glucagon administration also
decreases food intake, possibly by modulating vagal tone
and gastric emptying [97, 98]. Schulman et al. [99] reported
that glucagon reduces food intake and body weight but
caused hyperglycemia. However, the administration of the
dual agonists stimulating both glucagon and GLP-1 receptors
achieved improvement of diet-induced obesity and glucose
intolerance [100, 101]. It is, therefore, plausible that dual
agonism of glucagon and GLP-1 receptors may oﬀer novel
targets for antiobesity treatment.
2.5. Ghrelin. Ghrelin was identified originally as an endoge-
nous ligand for the growth hormone secretagogue receptor
(GHS-R) in rat stomach [102]. Ghrelin comprises a chain
of 28 amino acids with esterification of the hydroxyl group
of the third serine residue by octanoic acid, and it is the
only known orexigenic gut hormone. Ghrelin is principally
secreted from X/A-like cells within gastric oxyntic glands
[103]. In keeping with this, gastrectomy results in an 80%
reduction of plasma ghrelin levels; the remainder is secreted
from the intestine, pancreas, pituitary, and colon [104].
Ghrelin also acts as a neurotransmitter, being expressed
within the ARC and periventricular area of the hypothalamus
[102, 105].
Serum ghrelin levels are increased by fasting and
decreased by refeeding or oral glucose administration, but
they are not decreased by water ingestion [106]. In rats,
ghrelin levels show a diurnal pattern, with the bimodal peaks
occurring before dark and light periods [107]. In humans,
ghrelin levels have a diurnal rhythm which is identical to
the diurnal rhythm of leptin, with both hormones rising
throughout the day to a zenith at 0100 h, then falling
overnight to a nadir at 0900 h [108].
Levels of circulating ghrelin rise preprandially and fall
rapidly in the postprandial period [108]. Both central and
peripheral administration of ghrelin increase food intake
and body weight along with a reduction in fat utilisation in
rodents [106, 109]. Negative correlations between circulating
ghrelin levels and body mass index are found in human.
Fasting plasma levels of ghrelin are reported to be high in
patients with anorexia nervosa [110] and subjects with diet-
induced weight loss [111]. In contrast, obese subjects show
a less marked drop in plasma ghrelin after meal ingestion
[112]. In patients with heart failure, increased levels of
plasma ghrelin are reported in cachectic patients when
compared with noncachectic patients [113]. Furthermore,
in patients with PWS, elevated circulating ghrelin levels are
found, when compared with individuals with nonsyndromic
forms of obesity [114].
Ghrelin mediates its orexigenic action via stimulation
of NPY/agouti-related peptide (AgRP) coexpressing neurons
within the ARC of hypothalamus. Peripheral administration
of ghrelin increases c-fos expression in the ARC NPY/AgRP
neurons [115] and ablation of both AgRP and NPY neurons
completely abolishes the orexigenic eﬀect of ghrelin [116].
The brainstem and vagus nerve may also contribute to the
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eﬀects of ghrelin on food intake. ICV injection of ghrelin
induces c-fos expression in the NTS and AP [117]. GHS-R
is found to be expressed in the vagus nerve. Furthermore,
blockade of gastric vagal aﬀerents in rats abolishes ghrelin-
induced feeding and prevents the ghrelin-induced rise in c-
fos expression within the ARC [118]. In addition to its potent
orexigenic property, ghrelin also increases gastric motility,
upstimulates the hypothalamo-pituitary-adrenal axis, and
possesses cardiovascular eﬀects such as vasodilatation and
enhanced cardiac contractility [104].
Ghrelin may promote food intake in part by enhancing
the hedonic responses to food cues, which is demonstrated
by the recent study by Malik et al. [119]. In their study,
functional MRI was performed during exposure to food
pictures, and the study results demonstrated increased
activation in the amygdala, orbitofrontal cortex, anterior
insula, and striatum, during intravenous infusion of ghrelin.
2.6. Obestatin. Obestatin is a 23-amino acid peptide hor-
mone which is derived from posttranslational cleavage of
preproghrelin, and released from the stomach [120]. In
contrast to ghrelin which has orexigenic properties, obestatin
may have anorectic eﬀects by decreasing food intake,
delaying gastric emptying, and reducing body weight in
rodents [121]. However, the potential anorectic of obestatin
remains controversial, since other investigators have failed to
demonstrate eﬀects on food intake in lean or obese rodents
[122].
2.7. Cholecystokinin (CCK). CCK was the first gut hormone
found to be implicated in appetite control [123]. CCK is
secreted postprandially by the I cell of the small intestine
into circulation [124], with a short plasma half-life of a few
minutes. Plasma CCK levels rise within 15 minutes after
meal ingestion [124]. Infusion of C-terminal octapeptide of
CCK decreased food intake in 12 lean men [125]. However,
intermittent prandial CCK infusion reduces meal size in
rats but causes a compensatory increase in meal frequency
[126]. A 2-week continuous intraperitoneal infusion of CCK
failed to suppress food intake at any time point [127].
Other physiological functions of CCK include stimulating
the release of enzymes from the pancreas and gall bladder,
promoting intestinal motility, and delaying gastric emptying.
There are two CCK receptor subtypes known; CCK1 and
CCK2 receptors, previously classified as CCK A and CCK B.
The anorectic action of CCK appears to be mostly mediated
via CCK1 receptors on the vagal nerve [128, 129]. CCK 1
and 2 receptors are widely distributed in brain including the
brainstem and hypothalamus [130].
Some studies suggest that leptin and CCK may interact
synergistically to induce short-term inhibition of food intake
and long-term reduction of body weight [131]. Leptin-
deficient mice are insensitive to the meal-terminating eﬀect
of CCK administration. Furthermore, leptin signalling path-
ways to brain are dampened in the absence of interaction
with CCK release after a meal or in the setting of CCK-A
receptor blockade [132].
2.8. Amylin. Amylin is coreleased with insulin in response to
meal ingestion, and it may function as an anorectic hormone.
Circulating levels of amylin are found to be higher in obese
than lean subjects [133, 134]. Administration of amylin
is associated with reduced food intake and body weight
[135]. The anorectic eﬀects of amylin may be mediated
by modulating activity of the serotonin, histamine, and
dopaminergic system in the brain as well as inhibition
of NPY release [133]. Administration of pramlintide, a
synthetic analogue of human amylin, improves glycaemic
control and causes weight loss in type 2 diabetes patients
using insulin [136]. Therefore, amylin replacement with
pramlintide as an adjunct to insulin has been reported as
a novel physiological approach toward improved long-term
glycaemic and body weight control in patients with diabetes
[137].
3. Peripheral Adiposity Signals
3.1. Insulin. Circulating levels of insulin and leptin positively
correlate with adipose tissue mass within the body. Both
insulin and leptin are implicated in the long-term regulation
of energy balance. Insulin is synthesized in the ß cells of
the pancreas and is secreted rapidly after a meal, with well-
characterised hypoglycaemic eﬀects [138]. However, insulin
also acts as an anorectic signal within the CNS. ICV admin-
istration of insulin results in a dose-dependent suppression
of food intake and body weight gain in baboons and rodents
[139, 140]. Intrahypothalamic insulin injection to the PVN
also results in decreased food intake [141]. Insulin enters the
CNS through a saturable and receptor-mediated transport
process [142]. Insulin receptors are widely expressed in the
brain, particularly in hypothalamic nuclei, such as the ARC,
DMN, and PVN, which are involved in control of food
intake [143]. Although the mechanism of insulin-mediated
anorexia has not been fully elucidated, hypothalamic NPY
seems to be involved. ICV administration of insulin inhibits
the fasting-induced increase in NPYmRNA expression in the
PVN and ARC in rats. This suggests that fasting increases
NPY biosynthesis through an ARC-PVN pathway in the
hypothalamus via a mechanism which is dependent on low
insulin levels [144].
3.2. Leptin. Leptin is the product of the ob gene, and it is
predominantly secreted by adipocytes with circulating levels
proportional to fat mass [145]. Levels of circulating leptin
have a diurnal and pulsatile pattern, with peak levels at night
[146]. Leptin is transported across the BBB by a saturable
transporter system [147], and it exerts its anorectic eﬀect via
the ARC, where both NPY/AgRP and pro-opiomelanocortin
(POMC)/cocaine- and amphetamine-regulated transcript
(CART) neurons express leptin receptors [148]. Leptin
inhibits NPY/AgRP neurons and activates POMC/CART
neurons [149, 150], resulting in reduced food intake [149]
and increased energy expenditure [151]. The eﬀects of gut
satiation signals such as CCK can be amplified by leptin
which acts in the CNS, including the ARC in particular [152].
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There are three types of leptin receptors identified: long,
short, and secreted form [153]. Among those, Ob-Rb recep-
tor, which is highly expressed in the hypothalamus [154],
is thought to act as the main receptor involved in appetite
control. The db/db mouse, with an inactivating mutation in
the Ob-Rb receptor, has an obese phenotype [155, 156], and
leptin-deficient ob/ob mice exhibit hyperphagia and obesity,
which can be reversed by leptin administration [157].
Subcutaneous administration of recombinant leptin
reduces fat mass, hyperinsulinaemia, and hyperlipidaemia
in obese children with congenital leptin deficiency [158].
However, obese individuals often have high leptin levels,
which result in a failure to respond to exogenous leptin.
This leptin resistance severely limits the therapeutic utility of
leptin, and it is likely to result from reduced leptin receptor
signal transduction [159] or an impaired ability of the BBB
to transport leptin [160].
4. Neural Pathways Related to
the Appetite Control
Feeding and energy expenditure are controlled by com-
plex neural networks distributed throughout the forebrain
and brainstem. Reward-related neural brain regions have
been implicated in the nonhomeostatic control of feeding
behaviour [161]. By contrast, homeostatic feeding behaviour
is integrated within the hypothalamus. Key peripheral signals
of energy status such as gut hormones and adipokines
either signal to the hypothalamus directly or signal to
the hypothalamus indirectly via the brainstem and vagal
aﬀerent fibres. Adiposity signals such as insulin and leptin
are involved in the long-term energy homeostasis, and gut
hormones such as PYY, GLP-1, PP, OXM, and ghrelin are
implicated in the short-term regulation of meal ingestion
[162–164].
5. The Hypothalamus
The hypothalamus controls feeding by integrating peripheral
humoral signals that influence food intake and energy
expenditure, with neural signals from the brainstem and
higher cortical centres. The importance of the hypothalamus
in energy homeostasis was first suggested by classic lesioning
experiments in rodents [165]; subsequent studies have
suggested a role of hypothalamic nuclei, such as arcuate
nucleus (ARC), paraventricular nucleus (PVN), ventrome-
dial nucleus (VMN), dorsomedial nucleus (DMN), and
lateral hypothalamic area (LHA) in energy homeostasis.
In the ARC, there are two important discrete neu-
ronal populations: neurons which coexpress neuropeptide
Y (NPY) and agouti-related peptide (AgRP) stimulate food
intake, whereas neurons coexpressing pro-opiomelanocortin
(POMC) and cocaine- and amphetamine-regulated tran-
script (CART) suppress food intake (Figure 1). The ARC
is located at the base of median eminence which may be
accessed by circulating hormones likely due to its deficient
blood-brain barrier (BBB) [166] or by carrier-mediated
transport.
Cleavage of a precursor protein, called POMC, produces
α-melanocyte-stimulating hormone (α-MSH), which binds
to melanocortin-3 receptor (MC3R) and melanocortin-4
receptor (MC4R) to suppress food intake [167]. The MC4R
is highly expressed in the hypothalamus and is thought to
have a major role in suppressing food intake compared to
the MC3R. MC4R knock-out mice have hyperphagia and
obesity [167]. MC3R-deficient mice also have increased fat
mass and reduced lean body mass [168]; however, selective
MC3R agonists fail to suppress feeding [169].
CART is the third most abundant transcript identified
within the hypothalamus and is mostly colocalized with
POMC in the ARC. ICV administration of CART suppresses
feeding, whereas ICV injection of CART antiserum increases
food intake [170]. However, CART injected directly into the
PVN or ARC of fasted rats causes an increase in food intake
at 1-2 hours postinjection [171], which suggests opposing
eﬀects of CART on food intake can be observed depending
on the site of administration. Hence, the physiological role
of CART in energy homeostasis is unclear.
NPY/AgRP neurons extensively project to the adjacent
hypothalamic nuclei, such as the PVN, DMN, and LHA.
AgRP and NPY are exclusively colocalized in ARC neurons,
both of which exert orexigenic eﬀects [172]. NPY is the most
abundant neuropeptide in the CNS [173]. ICV injection
of NPY stimulates food intake in rats [41] and repeated
daily bilateral PVN injection of NPY for 10 days causes an
approximately two-fold increase in daily food intake and
a six-fold increase in the rate of body weight gain [174].
The orexigenic eﬀect of NPY appears to be mediated by
stimulation of hypothalamic Y1 and Y5 receptors. AGRP was
isolated by its high-sequence homology with the Agouti coat
colour gene which is associated with yellow coat, obesity, and
increased body length in mice. AgRP is a potent-selective
antagonist at the MC3R and MC4R [175].
The PVN receives projections of NPY/AgRP and
POMC/CART from the ARC and contains neurons which
express the anorectic factors, thyrotropin-releasing hor-
mone, and corticotropin-releasing hormone. Microinjection
of orexigenic or anorexigenic signals, such as ghrelin, orexin-
A, CCK, leptin, and GLP-1 into the PVN alter food intake
and body weight [163]. While ICV injection of NPY into
the PVN causes hyperphagia and obesity [174], destruction
of the PVN causes hyperphagia and obesity [176]. This
finding implies that the PVN may have an inhibitory role
in food intake and body weight. The LHA also receives
projections from the ARC and contains two orexigenic neu-
ropeptides, melanin-concentrating hormone (MCH), and
orexin (hypocretin). Transgenic mice overexpressing MCH
develop obesity and insulin resistance [177]. Furthermore,
transgenic mice which are deficient in the prohormone
precursor of MCH or the MCH 1 receptor are lean [178].
Hypocretins 1 and 2 are produced by the groups of neurons
in the LHA [179]. These neurons project extensively to
the olfactory bulb, cerebral cortex, thalamus, hypothalamus,
brainstem, locus coeruleus, tuberomamillary nucleus, and
raphe nucleus. In addition to the orexigenic eﬀects on food
intake, orexin seems to also have a role in other physiological
















































Figure 1: The gut hormone signalling to the brain under fasted (a) and fed states (b). (a) During the fasting/preprandial state, ghrelin release
from the stomach acts upon the ARC and vagus to stimulate hunger. (b) In the postprandial state, release of anorectic hormones, PYY, GLP-1,
OXM, and PP from intestine act upon the ARC, brainstem, and vagus to cause satiety. ARC, arcuate nucleus; NPY/AgRP, neuropeptide Y and
agouti related peptide; POMC/CART, pro-opiomelanocortin, and cocaine- and amphetamine-regulated transcript; PVN, paraventricular
nucleus; GLP-1, glucagon-like peptide-1; PP, pancreatic polypeptide; PYY, peptide YY; OXM, oxyntomodulin.
functions such as regulation of blood pressure, the neu-
roendocrine system, body temperature, and the sleep-waking
cycle [180]. An impairment of hypocretin neurotransmission
has been associated with the pathology of human narcolepsy,
which is a chronic sleep disorder characterized by excessive
daytime sleepiness, cataplexy, hypnagogic hallucinations,
and sleep paralysis [181]. MCH-R1 antagonists may have
therapeutic potential for the treatment of obesity [182], but
further work is required to determine if their use would
be associated with adverse eﬀects attributable to the other
biological actions of orexin.
The DMN receives NPY/AgRP projections from the ARC
[183] and projects the α-MSH fibre to the PVN [162, 184].
DMN lesions cause hyperphagia and obesity, which suggests
a suppressive role in appetite [185]. In diet-induced mice,
an approximately 40-fold increase in NPY expression is
observed in the DMN and VMN when compared with
controls [186]. In the VMN, brain-derived neurotrophic
factor (BDNF) is highly expressed, and VMN BDNF neu-
rons suppress food intake through MC4R signalling [187].
Increased signalling in the VMN following an oral glucose
load has been observed [162]. Selective deletion of BDNF
neurons in the VMN and DMN of adult mice results in
hyperphagia and obesity [188].
Glucose sensing plays an important role of the brain.
Conventionally, glucose sensing is thought to involve
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glucokinase-dependent metabolism of glucose to ATP, which
then alters membrane excitability by modulating ATP-
dependent channels or transporters, such as ATP-inhibited
K+ channels (KATP). Recent studies, however, suggest that
glucose-excited and glucose-inhibited neurones are able
to sense glucose irrespective of such metabolic pathways.
Brain glucose sensors, specialized neurones which respond
to fluctuations in local extracellular glucose concentration,
have been found only in a few brain regions, in particular,
the hypothalamus and brainstem. Hypothalamic glucose-
sensing neurones are found in the LHA, ARC, and VMN,
and responsive neurons have been identified which either
increase firing rate (glucose-excited neurones) or decrease
firing rate (glucose-inhibited neurones) in response to ex-
tracellular glucose [189].
6. Brainstem
Within the brainstem, the dorsal vagal complex (DVC) plays
an important role in relaying peripheral signals via vagal
aﬀerent fibres from the gut to hypothalamus. The DVC
has projections to the hypothalamus and higher cortical
centres [190] and comprises the dorsal motor nucleus of
vagus (DVN), area postrema (AP), and the nucleus of the
tractus solitarius (NTS). NTS is an ideal position to integrate
peripheral signals due to its close proximity to the AP, which
has an incomplete BBB [163].
Other than ascending brainstem-hypothalamus path-
ways, descending hypothalamic projections to the brainstem
are also important in control of food intake. α-MSH
projections from POMC neurons in the ARC terminate
in close anatomical proximity to neurons in the NTS,
which respond to gastric distension [191]. Furthermore,
descending projections from the LHA to the NTS contain
orexin andMCH, and descending ARC-parabrachial nucleus
pathways have been identified [152]. The PVN projects
regions of the midbrain such as the ventral tegmental area,
Edinger-Westphal nucleus, ventrolateral periaqueductal gray
matter, reticular formation, pedunculopontine tegmental
nucleus, and dorsal raphe nucleus. The PVN also projects
to the prelocus coeruleus in the dorsal pons as well as the
nucleus ambiguous and NTS in the ventral medulla. The
medial NTS receives the most extensive projections of the
PVN, substantially more than the DVN or AP [192].
The importance of the hindbrain in energy homeostasis
is highlighted by considering that chronically maintained
decerebrate rats, with complete high mesencephalic tran-
section, remain responsive to taste stimuli and respond to
intake-inhibitory feedback from the gut; however, hyper-
phagic response to food deprivation is not observed in these
animals [193]. Direct delivery of leptin to the lateral or
third ventricle as well as the fourth ventricle significantly
suppresses food intake up to 24 h after treatment [193].
The eﬀects of various gut hormones on food intake are
attenuated by lesions of the area postrema [194] or vagotomy
[28, 29, 118, 195]. Taken together, these findings suggest
brainstem-mediated mechanisms on controlling food intake.
The expression of leptin and insulin receptors, and of
glucose sensing mechanisms in the brainstem, is similar
to that seen in the hypothalamus [193]. POMC neurons
exist within the NTS, which show STAT-3 activation in
response to leptin administration to suppress food intake
[196]. Administration of leptin into the DVC suppresses food
intake [193].
In addition to the hypothalamus, the vagus nerve plays a
central role in regulating the feeding. Vagal aﬀerent neurons
have been shown to express a variety of receptors within
the brainstem, which include cholecystokinin (CCK) 1R and
CCK2R (at which both CCK and gastrin act [197]), Ob-
R [198], Y2R [29], GLP-1 [67], and GLP-2R [199], growth
hormone secretagogue receptor (GHS)-R1 where ghrelin
acts [118], and the orexin receptor, OX-R1 [200].
The vagal stretch and tension sensors detect nutrients
stored in the stomach. The vagus nerve also helps to
transmit gut hormones signals such as CCK, ghrelin, PYY,
PP, and GLP-1, which are released by anticipation of meals
and the presence of food in the upper gastrointestinal
tract. Cell bodies of aﬀerent fibres of the abdominal vagus
nerve are located in the nodose ganglia, which project
to the DVC of brainstem. In rats, infusion of saline into
the stomach has been observed to reduce food intake to
similar extents to infusion of nutrients into the stomach
[201]; this phenomenon is likely to be attributable to vagal
nerve function. The vagus nerve participates in transmitting
the food-induced negative-feedback signals important for
determining meal size. Transection of all gut sensory vagal
fibres results in increased meal size and meal duration, but
does not block gastric preload-induced feeding suppression,
implying that vagal aﬀerent signals have a significant role in
satiety during spontaneous meals [202, 203]. Randich et al.
[204] utilized extracellular recordings from the vagus nerve,
and found that it transmits a satiety signal from the jejunum,
following activation by infusion of fatty acids.
The importance of the role of the vagus nerve in
transmitting peripheral signals has been demonstrated by
vagotomy or capsaicin treatment to abolish its eﬀect, and by
vagus nerve stimulation (VNS) to enhance its activity [205].
Low-frequency VNS in rats fed with a standard diet results
in decreased food intake and body weight [206]. Compared
with the sham group, obese minipigs received VNS did not
gain body weight and showed decreased food intake by
18%—the eﬀects lasted for 14 weeks [207]. Gil et al. [208]
reported that chronic VNS with 10Hz electrical impulses
in rats fed with a high-fat diet significantly decreased food
intake and body weight gain. In their study, significant
neuronal responses in the NTS and decreased serum leptin,
but increased ghrelin levels, were observed and also nesfatin-
1 levels tended to increase following VNS. This suggests that
VNS results in reductions in food intake and body weight by
increasing brain satiety signals through the vagal aﬀerents.
The close association of the vagal eﬀerent, sympa-
thetic, and enteric systems makes it diﬃcult to selec-
tively manipulate the vagus nerve. Genetic approaches to
modulate signalling of neurotrophin factors (e.g., BDNF
and neurotrophin-3), which are essential for vagal aﬀerent
development, may help to further elucidate the regulatory
role of the vagus nerve in gut physiology [209].
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7. Reward Systems
In humans, environmental cues, cognitive, reward, and emo-
tional factors play an important role in food intake which
may override homeostatic requirements [210]. The corticol-
imbic pathways are responsible for reward-associated feeding
behaviour, which include the striatum, ventral tegmental
area, nucleus accumbens, insular cortex, anterior cingulate
cortex, and orbitofrontal cortex. The orbitofrontal cortex
is associated with regulating gustatory, olfactory, visual,
and somatosensory function, and sensory factors, such as
taste and smell, and has an important role in reward-
related feeding [211]. In patients with frontotemporal lobar
degeneration, hyperphagia is reported to be associated with
atrophy in the anterolateral orbitofrontal cortex [212].
The endocannabinoid and opioid systems have wide
receptor distributions within the CNS and play important
roles in reward-related feeding [213]. Administration of a μ-
opioid receptor agonist into the nucleus accumbens prefer-
entially stimulates intake of high-fat diet regardless of diet
preference at baseline, when both fat and carbohydrate diets
are displayed simultaneously [214]. Increased expression of
orexin in the hypothalamus has been observed following
administration of opioid μ-receptor agonists into the nucleus
accumbens [215]. Preadministration of a cannabinoid recep-
tor (CB1) antagonist prevents the orexigenic eﬀect of the
endocannabinoid agonist, anandamide on food intake [213].
Leptin has been shown to reduce endocannabinoid levels
in the hypothalamus [216]. This suggests that hypothala-
mic endocannabinoids may act via CB1 to increase food
intake through a leptin-regulated mechanism. The nucleus
accumbens (NAs) is a key region of limbic pathway and
may be implicated in regulation of hedonistic feeding and
homeostatic feeding [210].
The ventral striatum and population of dopamine neu-
rons of the substantia nigra are involved in the reward system
in human and nonhuman primates. The ventral striatum
receives input from the orbitofrontal cortex and anterior cin-
gulate cortex, which include the NA and the broad continuity
between the caudate nucleus and the putamen and the olfac-
tory tubercle [217]. Dopamine appears to be associated with
reward-related food intake and with behaviours required
to maintain feeding essential for survival. Mice lacking
dopamine, caused by the selective inactivation of tyrosine
hydroxylase, develop fatal hypophagia; and replacement of
dopamine in these animals to the caudate putamen or NA
restores preference for sucrose or palatable chow [218].
However, dopamine may have more complex eﬀects on
feeding, since dopamine signalling in the DMN and ARC of
hypothalamus may inhibit food intake [149].
In a recent positron emission tomography study, meal
ingestion was associated with greater activation of the
midbrain and middle-dorsal insula, and lesser activation
in the posterior cingulate cortex, temporal cortex, and or-
bitofrontal cortex following a meal in obese individuals
when compared with lean individuals [219]. In addition,
a study utilizing functional magnetic resonance imaging
(MRI) suggested that obese individuals had greater responses
to odours and fat rich food when compared with lean
subjects [220].
8. Nutrients and its Related Signals
Modulating Appetite
Although low-energy density diets induce short-term weight
loss [221], they are usually associated with rebound weight
gain. Some dietary patterns such as the Mediterranean-type
diet are associated with a decreased rate of cardiac death and
nonfatal myocardial infarction compared with a Northern
European or North American dietary pattern [222]. In the
Mediterranean diet, monounsaturated fat is substituted for
saturated and trans-fats, and intake of fruits, vegetables,
fibre, and whole grains are high, is recommended [223]. It is,
therefore, interesting to consider whether specific nutrients
within diets are able to modulate food intake, in addition to
eﬀects associated with their direct nutritional value.
The amino acid L-Glutamate is involved in multiple
physiologic functions, which include taste perception, car-
bohydrate metabolism, and excitatory neurotransmission in
the brain [224]. L-Glutamate stimulates its receptors in gut
epithelial cells, which activate cerebral regions such as basal
ganglia, limbic systems, and hypothalamus through vagal
aﬀerent nerve [225]. Kondoh et al. [226] reported that rats
with chronic ad libitum administration of monosodium
L-glutamate had reduced weight gain, fat deposition, and
plasma leptin concentrations when compared with controls.
In rodents, long-chain omega-3 polyunsaturated fatty
acids supplementation has been shown to improve obesity
[227]. In a recent study using a mouse model of diet-
induced obesity, ICV administration of unsaturated fatty
acids reduced hypothalamic inflammation, hypothalamic
and whole body insulin resistance, and body adiposity [228].
Free fatty acids exert insulin-like eﬀects in key brain areas
for energy homeostasis, including the ARC, possibly by
favouring intracellular accumulation of the long-chain fatty
acyl-CoA (LCFA-CoA) [229].
Unsaturated free fatty acid may, therefore, be beneficial
to treat obesity, although evidence in human is still limited.
Fructose is being increasingly used in processed foods
within the Western diet. However, its eﬀects may be distinct
to those of the related sugar, glucose. As glucose levels
entering to the brain increase, food intake is suppressed. In
contrast, fructose increases food intake when metabolized
in the brain. Fructose has the opposite eﬀect of glucose on
the AMP activated kinase/malonyl-CoA signaling system and
thereby enhances feeding behaviour [230].
Serotonin has a role in appetite control. 5HT-containing
neurons are organized into nine nuclei (B1–B9) which
are located in the midbrain and hindbrain. In particular,
the midbrain dorsal raphe (B7) contains a substantial
portion of the total brain 5HT neurons, with distinct
projections to hypothalamic nuclei and other feeding-related
forebrain areas [231]. 5-HT-stimulating drugs reduce food
intake partly mediated through the 5-HT2C receptor [232].
Although its eﬀects on eating behaviour remain to be
characterised, lorcaserin, a selective 5-HT2C receptor agonist
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Table 1: The summary of the role of gut hormones on appetite regulation and other actions.
Gut hormones Feeding Receptor Major secretion site Other actions
PYY3–36 ↓ Y2 L cells in gut Delays gastric emptying, inhibits gallbladder contraction, pancreaticexocrine secretions, and gastric acid secretion
PP ↓ Y4, Y5 PP cells in pancreas Delays gastric emptying, attenuates pancreatic exocrine secretion,
and inhibits gallbladder contraction
GLP-1 ↓ GLP-1 L cells in gut Incretin, decreases blood glucose, delays gastric emptying, and
neurotrophic eﬀect
OXM ↓ GLP-1 L cells in gut Inhibits gastric acid secretion and gastric emptying
Glucagon ↓ GCGR Pancreatic α cells Enhancing physiological response to stress
CCK ↓ CCK 1, 2 I cell of small intestine Gall bladder contraction, relaxation of sphincter of Oddi, and
pancreatic enzyme secretion
Ghrelin ↑ GHS stomach Growth hormone secretion, promotes gastric motility, vasodilatation,
and increases cardiac contractility
Amylin ↓ AMY1-3 pancreatic β cells Adiposity signals
PYY: peptide YY, PP: pancreatic polypeptide, GLP-1: glucagon-like peptide-1, OXM: oxyntomodulin, CCK: cholecystokinin, GCGR: glucagon receptor.
is reported to be a novel antiobesity drug reducing both food
intake and body weight.
Taste aﬀects food preference and intake. Lingual proteins
CD36 and GPR120 are reported to be responsible for
the spontaneous preference for lipid-rich foods [233] and
have been identified in human taste buds [234]. The gut
hormones such as GLP-1 and CCK and neurotransmitters
are also produced locally in taste buds [235]. Sweet and
umami taste are mediated by T1R family (T1R1, T1R2,
T1R3) which belongs to family C of GPCRs including
metabotropic glutamate receptors, calcium sensing recep-
tors, and V2r pheromone receptors. In the intestine, there
are diﬀerent sweet taste cells (enteroendocrine, brush cells)
within the epithelial layer. These sweet taste receptors may
signal through vagal aﬀerent fibres to alter food intake and
delay gastric emptying [236]. It has been shown that leptin
selectively suppresses sweet taste sensitivity or taste cells
through Ob-RB, whereas endocannabinoids enhance sweet
taste sensitivity of taste cells via CB1 receptor [237].
9. Bariatric Surgery
Whereas pharmacological and behavioural treatments are
usually associated with weight loss followed by weight regain,
bariatric surgery provides weight loss for at least 15 years, in
patients with obesity [238, 239]. Bariatric surgery is classified
into 3 types of surgical procedures; malabsorptive surgery,
restrictive surgery, and mixed procedures. Malabsorption-
based procedures include the jejuno-ileal bypass, which
results in decreased nutrients absorption by shortening the
functional small bowel length, and by allowing nutrients
to pass directly from the proximal jejunum to the terminal
ileum. Restrictive bariatric surgery includes the laparo-
scopic application of an adjustable gastric band, which is
associated with lower comorbidity when compared with
malabsorption-based procedures [240]. Roux-en-Y gastric
bypass (RYGB) is a combined restrictive and malabsorp-
tive procedure, which yields long-term, sustained period
of weight loss with an acceptable level of risk. RYGB
is thought to achieve its beneficial eﬀects through the
BRAVE eﬀects: Bile flow alteration, Reduction of gastric
size, Anatomical gut rearrangement and altered flow of
nutrients, Vagal manipulation, and subsequent Enteric gut
hormone modulation [241]. A decrease in levels of the
orexigenic hormone ghrelin, and an increase in levels of the
anorectic hormones PYY and GLP-1 have been observed
following bypass surgery [111, 242, 243]. An increase in
energy expenditure may play a role in part in weight loss
after gastric bypass surgery [244]. Moreover, microbial shifts
towards substantially higher concentrations of Proteobace-
ria, specifically Enterobacter hormaechei, are demonstrated
following RYGB surgery [241]. Gastric bypass surgery is
associated with greater improvements in glycaemic control
in patients with type 2 diabetes, when compared with gastric
banding procedures [245]. Furthermore these improvements
in glycaemic status often precede weight loss, which implies
that bypass surgery may have eﬀects in ameliorating type 2
diabetes which are additional to their eﬀects on body weight.
10. Gut Microbiota
A potential association between gut microbiota and the
pathogenesis of obesity has been recently recognised [246].
The human gut harbours a large number of 1000 to 1150
bacterial species collectively termed gut microbiota [247].
Adult germ-free mice have 40% less total body fat than
mice with normal microbiota; and replacing the microbiota
in adult germ-free mice is associated with a 60% increase
in body fat content and insulin resistance within 14 days
of replacement [248]. In contrast to mice with normal
gut microbiota, germ-free mice may be protected against
high fat diet-induced metabolic changes; increased fatty
acid metabolism, elevated levels of fasting-induced adipose
factor, Fiaf, known as angiopoietin-like protein-4, a secreted
lipoprotein lipase inhibitor, and increased AMP-activated
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protein kinase activity may play a role in this phenomenon
[249].
In a randomized, double-blind, parallel, placebo-
controlled study to evaluate the eﬀect of prebiotics on plasma
levels of gut hormones, 10 healthy subjects received either
16 g prebiotics/day or 16 g dextrin maltose/day for 2 weeks
[250]. In subjects following prebiotic treatment, increased
gut microbiota fermentation, decreased appetite, improved
postprandial glucose responses, and increased plasma levels
of GLP-1 and PYY were observed. Everard et al. [251]
reported that prebiotic administration led to specific gut
microbiota modulation, which improved glucose home-
ostasis, leptin sensitivity, and target enteroendocrine cell
activity in obese and diabetic mice. Furthermore, Muccioli
et al. [252] reported that gut microbiota may modulate
the intestinal endocannabinoid system tone, which in turn
regulates gut permeability and plasma lipopolysaccharide
levels.
Taken together, increasing evidence suggests that gut mi-
crobiota may be associated with the development of obesity,
and that prebiotics which modulate gut microbiota are
potential novel treatments for obesity.
11. Conclusion
Obesity is a global pandemic and major health burden
with associated risk factors of cardiovascular disease and
diabetes mellitus. Recent progress has been made in our
understanding of energy homeostasis, by characterising an
array of complex signalling pathways between the gut and
brain. However, no successful pharmacological treatments
for obesity have been developed, which can rival the
substantial weight loss associated with bariatric surgery.
However, bariatric surgery is restricted to patients with
morbid obesity, due to its perioperative risks. Modification
of the milieu of gut hormones is implicated in the sustained
weight loss observed following bypass surgery. In addition,
alterations in gut microbial flora following bypass surgery
may contribute to weight loss following bariatric surgery
[241]. These observations may help to develop a new
pharmacological strategy for patients with obesity. The roles
of the gut hormones on appetite regulation are summarised
in Table 1. Gut hormone-based therapeutics such as GLP-1R
agonists and DPP-IV inhibitors have already entered clinical
practice, and others are likely to follow. Mimicking the gut
hormone milieu observed following bariatric surgery may
help us to develop pharmacological therapeutics which lead
to substantial and sustained weight loss for patients with
obesity.
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